Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment
| Errataetall: |
CommentOn: Ann Oncol. 2023 Oct;34(10):948-949. - PMID 37499869 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Annals of oncology : official journal of the European Society for Medical Oncology - 34(2023), 10 vom: 26. Okt., Seite 949-950 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tarantino, P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
5384HK7574 |
|---|
| Anmerkungen: |
Date Completed 02.10.2023 Date Revised 15.10.2023 published: Print-Electronic ClinicalTrials.gov: NCT05840211, NCT04494425 CommentOn: Ann Oncol. 2023 Oct;34(10):948-949. - PMID 37499869 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.annonc.2023.07.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359998453 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359998453 | ||
| 003 | DE-627 | ||
| 005 | 20231226082051.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annonc.2023.07.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1199.xml |
| 035 | |a (DE-627)NLM359998453 | ||
| 035 | |a (NLM)37499870 | ||
| 035 | |a (PII)S0923-7534(23)00767-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tarantino, P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.10.2023 | ||
| 500 | |a Date Revised 15.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT05840211, NCT04494425 | ||
| 500 | |a CommentOn: Ann Oncol. 2023 Oct;34(10):948-949. - PMID 37499869 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a trastuzumab deruxtecan |2 NLM | |
| 650 | 7 | |a 5384HK7574 |2 NLM | |
| 650 | 7 | |a Immunoconjugates |2 NLM | |
| 650 | 7 | |a Trastuzumab |2 NLM | |
| 650 | 7 | |a P188ANX8CK |2 NLM | |
| 650 | 7 | |a Camptothecin |2 NLM | |
| 650 | 7 | |a XT3Z54Z28A |2 NLM | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Tolaney, S M |e verfasserin |4 aut | |
| 700 | 1 | |a Curigliano, G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology : official journal of the European Society for Medical Oncology |d 1990 |g 34(2023), 10 vom: 26. Okt., Seite 949-950 |w (DE-627)NLM012606308 |x 1569-8041 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2023 |g number:10 |g day:26 |g month:10 |g pages:949-950 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.annonc.2023.07.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2023 |e 10 |b 26 |c 10 |h 949-950 | ||